Business Context and Reporting Period
Company: Akers Biosciences, Inc. (ABI)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2013
Business Overview: ABI develops, manufactures, and supplies rapid, point-of-care screening and testing products. The company utilizes proprietary platform technologies (MPC Biosensor, PIFA, REA, and Rapid Blood Cell Separation) to create disposable tests for cardiology, infectious diseases, metabolism, and alcohol safety. ABI is a vertically integrated manufacturer operating from a single facility in Thorofare, New Jersey.
Key Financial Metrics
| Metric | 2013 | 2012 |
|---|---|---|
| Total Revenue | $3,577,851 | $1,564,101 |
| Gross Profit | $1,664,007 | $556,150 |
| Gross Margin | 47% | 36% |
| Net Loss | $(1,526,773) | $(2,557,820) |
| Accumulated Deficit | $(81,721,126) | $(80,194,353) |
| Cash and Cash Equivalents | $103,634 | $633,022 |
| Working Capital | $1,415,994 | $366,228 |
| Stockholders' Equity | $4,122,234 | $3,304,023 |
Revenue Composition (2013): Product revenue totaled $3,044,518 (including $1.72M from related party Chubeworkx). License revenue totaled $533,333 (including $333,333 from Chubeworkx).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 129% year-over-year, driven primarily by a 375% increase in MPC product sales and a 1,820% increase in licensing revenue.
- Customer Concentration: Chubeworkx Guernsey Limited became a dominant customer, accounting for 56% of total revenue in 2013 (up from negligible amounts in 2012). Combined with Cardinal Health and Fisher Healthcare, three customers accounted for approximately 85% of revenue.
- Profitability: While the net loss narrowed by approximately $1.03 million, the company remains unprofitable. Gross margin improved significantly to 47% due to higher licensing fees and production efficiencies.
- Cash Position: Cash and cash equivalents decreased by approximately $529,000 to $103,634, despite a $2.13 million cash inflow from financing activities (including private placements and related party notes).
- Equity Transactions: The company issued 512,820 shares to Chubeworkx for $1.6 million and converted 10 million Series A Preferred shares held by Thomas Knox into common stock.
Guidance, Outlook, Risks, and Contingencies
Outlook and Guidance: Management expects to continue incurring losses in the near term due to ongoing product development, clinical trials, and regulatory costs. The company believes its current working capital is sufficient to meet estimated cash needs for at least 12 months following its January 2014 IPO. Future capital requirements may necessitate additional equity or debt financing.
Key Risks:
- Customer Concentration: Heavy reliance on Chubeworkx (56% of revenue) and two distributors (Cardinal Health and Fisher Healthcare) creates significant vulnerability if these relationships are terminated.
- Regulatory Approval: Several pipeline products (e.g., Breath Ketone "Check", Breath PulmoHealth "Check") require FDA 510(k) clearance or CE marking. Failure to obtain these approvals would prevent commercialization.
- Intellectual Property: The company faces potential litigation regarding patent royalties and trade secrets. A dispute with Rapid Breath Diagnostics, LLC (RBD) regarding the "Ketone Check" and "Metron" products resulted in a $250,000 damage claim (subsequently litigated in 2014).
- Going Concern: The company has a history of operating losses and an accumulated deficit exceeding $81 million. Continued losses could impair the ability to continue as a going concern without additional financing.
- Compliance: The company disclosed a potential violation of Section 402 of the Sarbanes-Oxley Act regarding a promissory note issued to a director, which was subsequently cancelled and settled via stock issuance.
Investor Verification Checklist
- Customer Dependency: Verify the stability of the Chubeworkx agreement and the risk of revenue collapse if this single customer (56% of sales) reduces orders or terminates the contract.
- Cash Runway: Confirm the sufficiency of the $103,634 cash balance and the status of the January 2014 IPO proceeds ($13.1M net) to fund operations through the next 12-18 months.
- Regulatory Status: Monitor the progress of FDA 510(k) submissions for pipeline products, specifically Breath Ketone "Check" and Breath PulmoHealth "Check," as these are critical for future revenue diversification.
- Legal Contingencies: Track the outcome of the litigation against Rapid Breath Diagnostics, LLC regarding intellectual property rights and potential damages.
- Related Party Transactions: Review the terms of the Chubeworkx license agreement and the settlement of the Thomas Knox promissory note to ensure fair value and compliance with corporate governance standards.